

**2<sup>nd</sup>** PANHELLENIC CONGRESS OF MEDICAL PHYSICS  
4-6 OCTOBER 2024 | EUGENIDES FOUNDATION

# **“Novel hybrid DSPC:P(OEGMA-co-LMA) nanoplatforms: Exploring the design parameters affecting their performance”**

Efstathia Triantafyllopoulou<sup>1</sup>, Dimitrios Selianitis<sup>2</sup>, Anastasia Balafouti<sup>2</sup>, Nefeli Lagopati<sup>3</sup>, Maria Gazouli<sup>4</sup>, Georgia Valsami<sup>1</sup>, Stergios Pispas<sup>2</sup>, Natassa Pippa<sup>1</sup>

<sup>1</sup>Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece

<sup>2</sup>Theoretical and Physical Chemistry Institute, National Hellenic Research Foundation, Athens, Greece

<sup>3</sup>Department of Histology and Embryology, National Kapodistrian University of Athens, Athens, Greece

<sup>4</sup>Department of Basic Medical Science, National and Kapodistrian, University of Athens, Athens, Greece

# 1. Background-Aim

## Hybrid Nanoparticles-Definition


- Nanocarriers, composed of **two or more different biomaterials**, which maintain the biophysical properties of all components.

## Main advantages

- Nanoscale
- **Modified and Targeted Release**
- Incorporation of multiple therapeutic drugs and/or **drugs with challenging properties**
- **Decrease of disadvantages of individual nanoparticles** (toxicity, in vivo stability, solubility)
- **New intrinsic properties**


## Main Scope

Elucidation of the **design parameters** affecting hybrid nanoparticles' behavior regarding:





Development of **robust** and **well-defined** hybrid **lipid/random copolymer** structures as potential carriers

## 2. Materials & Methods



1,2-dioctadecanoyl-sn-glycero-3-phosphocholine (**DSPC**)



**statistical (random)** copolymers of oligo(ethylene glycol) methyl ether methacrylate (**OEGMA**) and lauryl methacrylate (**LMA**)

Hybrid systems of different

- length of OEGMA chain
- comonomer ratio
- lipid to polymer ratio

copolymer-1	copolymer-2	copolymer-3	copolymer-4
69%	51%	64%	53%
31%	49%	36%	47%



P(OEGMA)<sub>950</sub> segment



P(OEGMA)<sub>500</sub> segment




hydrophobic LMA segment




polymethacrylate backbone

## 2. Materials & Methods

---



### 3. Results - DSC




**Trends**

- Gradual loss of pretransition
- $\downarrow$   $T_{\text{onset}}$ ,  $T_m$ , and  $\Delta H$  by  $\uparrow$  copolymer

- **Successful incorporation** of the copolymers into DSPC bilayers
- **Cooperative hybrid bilayers** *except DSPC with copolymers 3 and 4 above 20% weight*





### 3. Results – DLS and fluorescence spectroscopy



- $R_h = 50 - 320$  nm  
(for most of the structures)
- Systems with longer OEGMA chains are **smaller**
- $I_1/I_3 = 1.26-1.52$   
(rather polar microenvironment)

Exceptional behavior for each system due to random topology and different hydrophilic to hydrophobic balance

### 3. Results – Biological assessment




- **Dose dependent** - *biocompatibility at low concentration*
- **Mainly lipid to polymer dependent**
- **The most toxic:** DSPC:3 nanostructures
- **Biocompatible:** DSPC:1 (5:5) & DSPC:2 (9:1)
- **Dependent on %LMA and/or OEGMA chain length**  
 → **different co-assembly**

## 4. Conclusions

- **Successful fabrication of biocompatible DSPC:P(OEGMA-co-LMA) hybrid systems**

- **The main influential parameters:**



- **Future perspectives:**

---

Morphology

---

Microfluidity

---

Protein corona formation and in vivo stability

---

**Drug loading**

---

**Drug release kinetics**

Colloids and Surfaces A: Physicochemical and Engineering Aspects 684 (2024) 133015

Contents lists available at [ScienceDirect](#)

**Colloids and Surfaces A: Physicochemical and Engineering Aspects**

journal homepage: [www.elsevier.com/locate/colsurfa](http://www.elsevier.com/locate/colsurfa)

Fabricating hybrid DSPC:DOPC:P(OEGMA-co-LMA) structures:  
Self-assembly as the milestone of their performance

Efstathia Triantafyllopoulou<sup>a</sup>, Dimitrios Selianitis<sup>b</sup>, Anastasia Balafouti<sup>b</sup>, Nefeli Lagopati<sup>c</sup>,  
Maria Gazouli<sup>d</sup>, Georgia Valsami<sup>a</sup>, Stergios Pispas<sup>b,\*</sup>, Natassa Pippa<sup>a,\*\*</sup>

Check for updates




## 5. References

---

- Pippa N, Pispas S., and Demetzos C., 2015. Mixed Biocompatible Block Copolymer/Lipid Nanostructures as Drug Nanocarriers: Advantages and Pharmaceutical Perspectives. Vijay Kumar Th akur and Manju Kumari Th akur (eds.), Handbook of Polymers for Pharmaceutical Technologies, Volume 4 (259–286) © 2016 Scrivener Publishing LLC, 259-285.
- Sailor M. J. and Park J., 2012. Hybrid Nanoparticles for Detection and Treatment of Cancer. *Adv. Mater.* 2012, DOI: 10.1002/adma.201200653.
- Triantafyllopoulou E.; Selianitis D.; Balafouti A.; Lagopati N.; Gazouli M.; Valsami G.; Pispas S.; Pippa N. Fabricating hybrid DSPC:DOPC:P(OEGMA-co-LMA) structures: Self-assembly as the milestone of their performance. *Colloids Surf., A* 2024, 684, 133015. 10.1016/j.colsurfa.2023.133015.
- Zhang L., Chan J.M., Gu F.X., Rhee J., Wang, A.Z., Radovic-Moreno A.F., Alexis F., Langer R., and Farokhzad O. C., 2008. Self-Assembled Lipid Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform. *ACS Nano*, VOL. 2, NO. 8, 1696–1702.
- Zhang L. and Zhang L., 2010. Lipid-Polymer Hybrid Nanoparticles: Synthesis, Characterization and Applications. *Nano LIFE* ,Vol. 1, Nos. 1 & 2 (2010) 163-173.

**2<sup>nd</sup>** PANHELLENIC CONGRESS OF MEDICAL PHYSICS  
4-6 OCTOBER 2024 | EUGENIDES FOUNDATION

**Thank you for your attention!**

The bottom of the slide features a decorative graphic consisting of several overlapping, wavy lines in shades of teal and light blue, creating a sense of motion and depth against the dark background.